EP396: How to Answer This Question: Will Humira® Biosimilars Reduce Drug Spend? With Anna Hyde

How to Answer This Question: Will Humira® Biosimilars Reduce Drug Spend? With Anna Hyde (EP396)

Biosimilar Competition Alone Won't Lower Prices—Uptake Is What Actually Moves the Needle. Episode 396.

Stacey Richter talks with Anna Hyde, VP of advocacy and access at the Arthritis Foundation, about why the arrival of a dozen Humira biosimilars in 2023 won't automatically lower drug spend—and what has to happen for prices to actually come down.

WHAT YOU'LL LEARN

✅ Why having competitors on the market doesn't erode a monopoly without real patient and provider uptake

✅ How manufacturer rebates keep PBMs "addicted" to the reference product even after biosimilars launch

✅ Why provider and patient confidence in biosimilar interchangeability is just as important as market dynamics

✅ What tipping point in net pricing would be needed to force PBMs to prefer biosimilars over Humira

✅ Why clear, proactive communication prevents patients from feeling blindsided by a switch to an unfamiliar delivery device

✅ What health plans should be doing right now to prepare for a thoughtful biosimilar transition

WHY THIS MATTERS

Competition on paper doesn't guarantee lower prices in practice—it takes real patient and provider uptake to break a rebate-driven monopoly. Hyde's advice gives health plans a communication-first roadmap for actually reaching the tipping point where biosimilar savings materialize, rather than assuming market dynamics will handle it alone.

MENTIONED IN THIS EPISODE

No past-episode citations in this episode's timestamped chapter list.

=== LINKS ===

🔗 Show Notes with all mentioned links: Episode Page

✉️ Enjoy this podcast? Subscribe to the free weekly newsletter

🫙 Support the podcast with a small donation to the Tip Jar

📺 Subscribe to our YouTube channel

🎤 Listen on Apple Podcasts

🎤 Listen on Spotify

=== CONNECT WITH THE RHV TEAM ===

✭ LinkedIn ✭ Threads ✭ Bluesky ✭ X

00:00 Introduction.

07:38 What does a successful biosimilar market depend on?

09:07 Why does uptake seem to reduce prices?

10:24 How important is the relationship with the healthcare provider?

11:35 Where are we in getting these biosimilars to market?

13:02 Are there differences between the reference product and biosimilars?

19:26 Why does the way you approach the patient matter?

22:36 Why do providers feel like they don't have a lot of agency in the biosimilar conversation?

24:50 What should health plans be thinking if they want to go down the biosimilar path?

27:36 "Our goal is to keep a feedback loop such that no patient falls through the cracks."

28:21 What is the "nocebo" effect?

31:27 What is Anna's advice to plan sponsors on communicating with providers and plan sponsors?